Legal & General Group
UBX

Legal & General Group’s Unity Biotechnology UBX Stock Holding History

Legal & General Group’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-389
Closed -$23K – 3649
2021
Q1 		$23K Sell
389
-24
-6% -$1.64K ﹤0.01% 3078
2020
Q4 		$22K Hold
413
– – ﹤0.01% 3059
2020
Q3 		$14K Sell
413
-127
-24% -$8.04K ﹤0.01% 3105
2020
Q2 		$47K Buy
540
+82
+18% +$6.08K ﹤0.01% 2748
2020
Q1 		$27K Sell
458
-103
-18% -$6.49K ﹤0.01% 2805
2019
Q4 		$40K Buy
561
+83
+17% +$5.86K ﹤0.01% 2911
2019
Q3 		$29K Hold
478
– – ﹤0.01% 2985
2019
Q2 		$40K Buy
478
+92
+24% +$7.83K ﹤0.01% 2875
2019
Q1 		$31K Hold
386
– – ﹤0.01% 2918
2018
Q4 		$63K Buy
386
+311
+415% +$41.3K ﹤0.01% 2606
2018
Q3 		$12K Hold
75
– – ﹤0.01% 3304
2018
Q2 		$11K Buy
+75
New +$11K ﹤0.01% 3294

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Legal & General Group's UBX Position: Q2 2021 in Review

Legal & General Group sold out of Unity Biotechnology (UBX) in Q2 2021, closing a stake of 389 shares — an estimated $23K sold.

Legal & General Group first reported a position in UBX in Q2 2018 and held it in 12 quarters. The position peaked at $63K in Q4 2018. 98 funds tracked by Wall St. Rank hold UBX as of Q2 2021.

  • Legal & General Group reported no remaining Unity Biotechnology position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 389 Unity Biotechnology shares in Q2 2021, an estimated $23K.
  • Legal & General Group first reported a position in Unity Biotechnology in Q2 2018 and held it in 12 quarters.
  • Legal & General Group's Unity Biotechnology position peaked at $63K in Q4 2018.
  • 98 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.